Literature DB >> 22889772

Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.

Yumiko Okada1, Takashi Nihashi, Masazumi Fujii, Katsuhiko Kato, Yoshiyuki Okochi, Yoshio Ando, Masato Yamashita, Satoshi Maesawa, Shigenori Takebayashi, Toshihiko Wakabayashi, Shinji Naganawa.   

Abstract

PURPOSE: The aim of our study was to examine the usefulness of PET with C-methionine (MET) and F-fluorodeoxyglucose (FDG) in the differentiation of glioblastoma multiforme (GBM) and intracranial diffuse large B-cell lymphoma (DLBCL).
MATERIALS AND METHODS: We evaluated 22 patients retrospectively with an enhancing brain tumor on MRI, including 15 GBM and 7 DLBCL, which was confirmed by histopathology. Dynamic PET scans with MET and FDG were performed for preoperative differential diagnosis. We assessed the images qualitatively and quantitatively. In quantitative assessment, the SUVmax was used on FDG PET and both late and early phases on MET PET. In addition, the ratio of SUVmax in the late and early phases on MET-PET was evaluated (ΔSUVmax).
RESULTS: SUVmax on FDG PET of DLBCL was significantly higher than that of GBM. Setting an SUVmax of 12.0 as the cutoff for differentiating DLBCL from GBM, 1 GBM and 1 DLBCL were found to be false-positive and false-negative, respectively.SUVmax in the late and early phases of MET-PET was not significantly different between DLBCL and GBM; however, we also found significant differences in ΔSUVmax on MET-PET. Using ΔSUVmax 1.17 as the cutoff, we could differentiate DLBCL from GBM completely. In the present study, ΔSUVmax on MET-PET was slightly superior to SUVmax on FDG PET.
CONCLUSIONS: Both SUVmax on FDG PET and ΔSUVmax on MET-PET were considered to be good diagnostic tests when encountering difficulties in this differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889772     DOI: 10.1097/RLU.0b013e318262af48

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  10 in total

1.  Characteristics of time-activity curves obtained from dynamic 11C-methionine PET in common primary brain tumors.

Authors:  Yuichi Nomura; Yoshitaka Asano; Jun Shinoda; Hirohito Yano; Yuka Ikegame; Tomohiro Kawasaki; Noriyuki Nakayama; Takashi Maruyama; Yoshihiro Muragaki; Toru Iwama
Journal:  J Neurooncol       Date:  2018-03-21       Impact factor: 4.130

2.  MR imaging based fractal analysis for differentiating primary CNS lymphoma and glioblastoma.

Authors:  Shuai Liu; Xing Fan; Chuanbao Zhang; Zheng Wang; Shaowu Li; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal:  Eur Radiol       Date:  2018-08-30       Impact factor: 5.315

3.  Preliminary clinical assessment of dynamic carbon-11 methionine positron-emission tomography/computed tomography for the diagnosis of the pathologies in patients with musculoskeletal lesions: a prospective study.

Authors:  Takayoshi Shinya; Yoichi Otomi; Toshihiko Nishisho; Bettina Beuthien-Baumann; Michiko Kubo; Hideki Otsuka; Yoshimi Bando; Hiroaki Yanagawa; Koichi Sairyo; Masafumi Harada
Journal:  Eur J Hybrid Imaging       Date:  2020-08-26

Review 4.  Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas.

Authors:  Kamalakannan Palanichamy; Arnab Chakravarti
Journal:  Front Oncol       Date:  2017-11-01       Impact factor: 6.244

5.  [18F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [18F]FDG in human xenograft models.

Authors:  Narinée Hovhannisyan; Fabien Fillesoye; Stéphane Guillouet; Méziane Ibazizene; Jérôme Toutain; Fabienne Gourand; Samuel Valable; Benoit Plancoulaine; Louisa Barré
Journal:  Theranostics       Date:  2018-08-10       Impact factor: 11.556

6.  Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.

Authors:  Meetakshi Gupta; Tejpal Gupta; Nilendu Purandare; Venkatesh Rangarajan; Ameya Puranik; Aliasgar Moiyadi; Prakash Shetty; Sridhar Epari; Ayushi Sahay; Abhishek Mahajan; Amit Janu; Bhausaheb Bagal; Hari Menon; Sadhana Kannan; Rahul Krishnatry; Goda Jayant Sastri; Rakesh Jalali
Journal:  CNS Oncol       Date:  2019-11-29

7.  Use of 18F-FDG-PET/CT in differential diagnosis of primary central nervous system lymphoma and high-grade gliomas: A meta-analysis.

Authors:  Guisheng Zhang; Jiuhong Li; Xuhui Hui
Journal:  Front Neurol       Date:  2022-08-17       Impact factor: 4.086

8.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30

Review 9.  Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.

Authors:  Yaru Zou; Jianjing Tong; Haiyan Leng; Jingwei Jiang; Meng Pan; Zi Chen
Journal:  Oncotarget       Date:  2017-06-20

Review 10.  Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.

Authors:  C Chiavazza; A Pellerino; F Ferrio; A Cistaro; R Soffietti; R Rudà
Journal:  Biomed Res Int       Date:  2018-06-21       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.